Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of the present study was to evaluate the treatment outcome of homoharringtonine, cytarabine (AraC) and aclarubicin combination therapy as induction treatment for
myelodysplastic syndromes
-refractory anemia with excess blasts (MDS-RAEB). A total of 24 patients with
MDS
-RAEB who were aged between 18 and 66 years were treated with homoharringtonine, AraC and aclarubicin (
HAA
regimen). The
HAA
regimen consisted of homoharringtonine (2 mg/m
2
intramuscularly twice daily, days 1-3), AraC (75 mg/m
2
injected subcutaneously twice daily, days 1-7) and aclarubicin (12 mg/m
2
, days 1-7). The overall response rate was 79% with a complete remission rate of 58.3% and partial remission rate of 20.7%. There was no evidence of early mortality in this group of patients. The median overall survival (OS) was 36.2 months (95% confidence interval, 24.6-47.4 months), and the estimated three year overall survival rate was 45.8%. In conclusion,
HAA
combination therapy is a suitable induction regimen for patients with
MDS
-RAEB, which may improve the outcome for
de novo
higher-risk
MDS
patients, particularly of those with favorable and intermediate cytogenetics.
...
PMID:Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB. 2687 Feb 17
